ARCT-810 is under clinical development by Arcturus Therapeutics and currently in Phase I for Ornithine-Transcarbamylase Deficiency. According to GlobalData, Phase I drugs for Ornithine-Transcarbamylase Deficiency does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ARCT-810 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ARCT-810 overview

ARCT-810 is under development for the treatment of ornithine transcarbamylase (OTC) deficiency. It is administered through the intravenous route. The drug candidate is an ornithine transcarbamylase (OTC) mRNA. It is developed based on lipid-enabled and unlocked nucleic acid modified RNA delivery technology (LUNAR) a LNP based platform and manufactured by NanoAssemblr technology. It acts by targeting periportal hepatocytes.

Arcturus Therapeutics overview

Arcturus Therapeutics (Arcturus) is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for the treatment of diseases. The company discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery systems. Its pipeline products portfolio includes ARCT-810 (LUNAR-OTC) and ARCT-032 (LUNAR-CF). Arcturus also developed ARCT-021 (LUNAR-COV19 Vaccine) and LUNAR Flu. It provides messenger RNA (mRNA), that is used as protein replacement therapy to treat diseases caused by a lack of protein and by defective proteins for cystic fibrosis. The company RNA Therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and COVID-19. Arcturus is headquartered in San Diego, California, the US.

For a complete picture of ARCT-810’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.